Immunotherapy for pancreatic and colorectal cancer

Current therapies have a limited efficacy and high toxicity levels. Based on a new theory concerning tumor growth, we are developing an innovative treatment based on immunotherapy to treat pancreatic and colorectal cancers with the goal of reaching a safe and effective therapy for the patient.

1

Most of the current approaches to treat cancer are based on the same idea: the use of drugs to generate toxicity in the tumor cells with the goal of killing as much cells as possible one by one. This approach has a critical lack of efficacy due the tumor's extraordinary ability to adapt. Tumor cells are continuously changing and generate resistance against treatments. The tumour treated in a chemotherapy cycle is therefore completely different from the one in the previous cycle. Furthermore, the use of toxic drugs produces many severe side effects.

2

Current paradigm considers that the tumor cells grow in a disorganized way; as if every cell would continuosly replicate without being affected by the other cells of the tumor. If this were so, the only possible treatment would be to eliminate each tumor cell one by one, or at least to reduce its count enough to allow a surgical removal of the remaining tumor. This is extremely complex and ineffective in most cases, especially when the tumor metastasizes.

3

New observations about tumor evolution offer a new theory about tumor growth: tumors don't grow in a disorganised way but rather they follow a specific physic pattern. This allows us to predict its evolution and therefore design a treatment to block its growth, interrupting the evolving pattern of the tumor and reverting its growth without generating toxicity.

At Endor, we explore this new approach to treat cancer, specially for pancreatic and colorectal cancers. Our research is ready to start clinical trials on phase II/a.